Patent · US Active

IgE antibodies for the treatment of cancer

US8697079B2 · kind B2 · utility

5Cited by

2References

18Claims

0Family size

Assignees

QUEST PHARMATECH INC. · CA
The Regents of the University of California · US

Inventors

Manuel L. Penichet · Los Angeles, US
Birgit Schultes · Arlington, US
Christopher F. Nicodemus · Franconia, US
Tracy R. Daniels · Calabasas, US
Gustavo Helguera · Springdale, US
JOSE A. RODRIGUEZ · Paramount, US

Key dates

Filing date	Feb 14, 2012
Grant date	Apr 15, 2014
Priority date	—
Expiry date	Feb 14, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/24
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.